This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read bioAffinity Technologies’s 8K filing here.
bioAffinity Technologies Company Profile
bioAffinity Technologies, Inc, a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level.
Further Reading
- Five stocks we like better than bioAffinity Technologies
- How to Find Undervalued Stocks
- IBM’s AI Bet Pays Off—What’s Next for Investors?
- What is the Euro STOXX 50 Index?
- 3 Reasons to Treat AMD’s Drop as an Entry Opportunity
- What is a Dividend King?
- Qualcomm’s Post-Earnings Dip: A Prime Buying Opportunity?
